Heart attack mystery: new study tracks SCAD patients to find answers

NCT ID NCT07317323

Recruiting now Knowledge-focused Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is following 300 people in Norway who have had a spontaneous coronary artery dissection (SCAD), a rare cause of heart attacks, especially in women. Researchers will use scans, blood tests, and questionnaires to track their health for one year. The goal is to better understand what leads to SCAD and what complications may arise, but no new treatments are being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could reveal key risk factors and long-term outcomes for SCAD, helping doctors better manage and prevent future events in patients.
What could go wrong: This is an observational study, not a treatment trial. It will not test any new therapy, so it cannot directly improve patient outcomes. Results may take years to influence clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION (MI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic spontaneous coronary artery dissection myocardial infarction short chain acyl-CoA dehydrogenase deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL INFARCTION (MI) SCAD WOMEN

Contacts and locations

Locations

Akershus University Hospital
RECRUITING

Oslo, Norway
Haukeland University Hospital
RECRUITING

Bergen, Norway
Rikshospitalet, Oslo University Hospital
RECRUITING

Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.